MTVA: New Data for Vanoglipel (DA-1241) Presented at AASLD
In November 2025, MetaVia Inc. (MTVA) announced new positive data from the Phase 2a clinical trial of vanoglipel (DA-1241) was presented at the...
291 Views
MTVA: New Date for Vanoglipel (DA-1241) Presented at AASLD
In November 2025, MetaVia Inc. (MTVA) announced new positive data from the Phase 2a clinical trial of vanoglipel (DA-1241) was presented at the...
247 Views
MTVA: 8-Week Data for 48 mg Cohort in Phase 1 Obesity Study Expected Before End of 2025
On November 6, 2025, MetaVia Inc. (MTVA) announced financial results for the third quarter of 2025 and provided a business update. We anticipate...
151 Views
MTVA: Results from 8-week Study of 48 mg DA-1726 Expected Before End of 2025
On August 7, 2025, MetaVia Inc. (MTVA) announced financial results for the second quarter of 2025 and provided a business update. The company...
130 Views
MTVA: DA-1241 in Combination with Efruxifermin Shows Additive Hepatoprotective Effects in Mouse MASH Model
On June 21, 2025, MetaVia Inc. (MTVA) announced the presentation of preclinical data for DA-1241, the company's novel GPR119 agonist, that showed...
285 Views